VISTAGEN : la ricetta per la felicità da sniffare...????

[BigNick]

Salva e' potenteLa prossima volta tocca piu' forte

Maledetto

 

[serenella6]

Maledetto

E' sempre lui ..ma gli voglio bene

 

[fred perry]

E' sempre lui ..ma gli voglio bene

quando venderà andremo a 3$....

 

[BigNick]

E' sempre lui ..ma gli voglio bene

che ci vuoi fare, tenerlo o ammazzarlo

 

[serenella6]

quando venderà andremo a 3$....

Infatti Quando lui parla, bisogna andare short..perche' viene giu' tutto Scherzi a parte..il mercato fa schifo!

 

[serenella6]

che ci vuoi fare, tenerlo o ammazzarlo

Sal non si tocca..e' uno dei nostri

 

[BigNick]

Infatti Quando lui parla, bisogna andare short..perche' viene giu' tutto Scherzi a parte..il mercato fa schifo!

Quasi tutto, la mia preferita sale ampiamente oggi

 

[Salva_Tori]

UNDICI GIORNI DI DISCESA CONTINUA
VORREI TANTO AVERE IN MANO CHI MANIPOLA QUESTO TITOLO

 

[BigNick]

UNDICI GIORNI DI DISCESA CONTINUA
VORREI TANTO AVERE IN MANO CHI MANIPOLA QUESTO TITOLO

c'è di buono che sbagliando si impara

 

[beppofinanza]

Altro acquisto a 0.1329 sperem

 

[Salva_Tori]

c'è di buono che sbagliando si impara

vero e anche il contrario : " OGGI HO MEDIATO " i romani dicevano
sbagliare è umano perseverare Salva_Tori

 

[serenella6]

UNDICI GIORNI DI DISCESA CONTINUA
VORREI TANTO AVERE IN MANO CHI MANIPOLA QUESTO TITOLO

Devi soffrire , ma , poi ti daremo un farmaco per il disturbo depressivo, senza effetti collaterali

 

[Salva_Tori]

Devi soffrire , ma , poi ti daremo un farmaco per il disturbo depressivo, senza effetti collaterali

no datemelo subito anche con gli effetti collaterali

 

[BigNick]

Devi soffrire , ma , poi ti daremo un farmaco per il disturbo depressivo, senza effetti collaterali

l'unico problema che avrai e che anzichè sniffarlo dovrai usare un bel suppostone

 

[Salva_Tori]

l'unico problema che avrai e che anzichè sniffarlo dovrai usare un bel suppostone

a buoni intenditori

 

[BigNick]

basta lubrificare un pò tranquillo....

 

[serenella6]

l'unico problema che avrai e che anzichè sniffarlo dovrai usare un bel suppostone

Per Salva..lo stiamo preparando in versione spray

 

[Salva_Tori]

Per Salva..lo stiamo preparando in versione spray

ok metto da parte la vasellina

 

[serenella6]

ok metto da parte la vasellina

Non si usa piu'..ormai lubrifichiamo con lo spray indolore Vediamo, se ce ne fanno trovare uno, dentro l'uovo di Pasqua

 

[serenella6]

On March 7, 2023, Vistagen Therapeutics, Inc. (the “Company”) received a letter (the “Extension Notice”) from the Listing Qualifications Staff of The Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company that Nasdaq has granted the Company a 180-day extension, until September 5, 2023 (the “Extension Period”), to regain compliance with the requirement for the Company’s common stock, par value $0.001 per share (“Common Stock”), to maintain a minimum bid price of $1.00 per share for continued listing on the Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”).

The Extension Notice has no immediate effect on the continued listing status of the Company's Common Stock on the Nasdaq Capital Market. The Company's listing on the Nasdaq Capital Market remains fully effective.

As previously disclosed in the Company’s Current Report on Form 8-K, filed on September 7, 2022, the Company received notice from Nasdaq that the Company was not in compliance with the Minimum Bid Price Requirement for a period of 30 consecutive business days (the “Initial Notice”). As provided in the Initial Notice, the Company had a 180-day period, until March 6, 2023, to regain compliance with the Minimum Bid Price Requirement. As of the date of this Report, the Company has not yet regained compliance with the Minimum Bid Price Requirement, and instead advised Nasdaq of its intent to cure the deficiency within the Extension Period.

The Company will continue to monitor the closing bid price of its Common Stock and seek to regain compliance with the Minimum Bid Price Requirement within the Extension Period. If the Company does not regain compliance with the Minimum Bid Price Requirement within the Extension Period, Nasdaq will provide written notification to the Company that its Common Stock will be subject to delisting, at which time the Company may appeal Nasdaq’s delisting determination to a Nasdaq Hearing Panel (the “Panel”). There can be no assurance that, if the Company does need to appeal a Nasdaq delisting determination to the Panel, that such appeal would be successful.

Item 9.01 Financial Statements and Exhibits.

On March 7, 2023, Vistagen Therapeutics, Inc. (the “Company”) received a letter (the “Extension Notice”) from the Listing Qualifications Staff of The Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company that Nasdaq has granted the Company a 180-day extension, until September 5, 2023 (the “Extension Period”), to regain compliance with the requirement for the Company’s common stock, par value $0.001 per share (“Common Stock”), to maintain a minimum bid price of $1.00 per share for continued listing on the Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”).

The Extension Notice has no immediate effect on the continued listing status of the Company's Common Stock on the Nasdaq Capital Market. The Company's listing on the Nasdaq Capital Market remains fully effective.

As previously disclosed in the Company’s Current Report on Form 8-K, filed on September 7, 2022, the Company received notice from Nasdaq that the Company was not in compliance with the Minimum Bid Price Requirement for a period of 30 consecutive business days (the “Initial Notice”). As provided in the Initial Notice, the Company had a 180-day period, until March 6, 2023, to regain compliance with the Minimum Bid Price Requirement. As of the date of this Report, the Company has not yet regained compliance with the Minimum Bid Price Requirement, and instead advised Nasdaq of its intent to cure the deficiency within the Extension Period.

The Company will continue to monitor the closing bid price of its Common Stock and seek to regain compliance with the Minimum Bid Price Requirement within the Extension Period. If the Company does not regain compliance with the Minimum Bid Price Requirement within the Extension Period, Nasdaq will provide written notification to the Company that its Common Stock will be subject to delisting, at which time the Company may appeal Nasdaq’s delisting determination to a Nasdaq Hearing Panel (the “Panel”). There can be no assurance that, if the Company does need to appeal a Nasdaq delisting determination to the Panel, that such appeal would be successful.

https://fintel.io/sf/us/vtgn?utm_source=stocktwits.com&utm_medium=Referral&utm_campaign=filing